Galantamine
Galantamine is a pharmaceutical drug with 51 clinical trials. Currently 2 active trials ongoing. Historical success rate of 84.4%.
Success Metrics
Based on 38 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
11
Mid Stage
24
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
82.6%
38 of 46 finished
17.4%
8 ended early
2
trials recruiting
51
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans
Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment
Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke
Effect of Galantamine on Inflammation and Cognition
Effects of Galantamine on Cognition
Clinical Trials (51)
Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans
Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment
Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke
Effect of Galantamine on Inflammation and Cognition
Effects of Galantamine on Cognition
An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Galantamine Effects on Cognitive Function in Abstinent Cocaine Users
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
Racial Differences in Vagal Control of Glucose Homeostasis
Effect of Galantamine on Short-term Abstinence
Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse
Cognitive Enhancement as a Target for Cocaine Pharmacotherapy
Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
Pharmacovigilance in Gerontopsychiatric Patients
Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance
A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 51